(updates with Nestle's comments)
Nestlé India (NSE:NESTLEIND, BOM:500790) is facing legal action initiated by The Food Safety and Standards Authority of India (FSSAI) after its baby food was found to be substandard, said in a social media post Friday.
A lab analysis of Nestlé India's Follow-up Formula was found "substandard with respect to Biotin content."
The regulator also said infant nutrition products NAN Excella Pro Stage 1 and Lactogen Pro 1 were found in breach of a regulation restricting promotional materials with the aim of boosting the saleability of infant foods.
In a statement to, Nestlé said it adheres to all regulations including all norms and label declarations as per applicable laws.
"Our products are fully compliant with all the applicable regulations. The said products (i.e., NAN EXCELLA PRO & LACTOGEN PRO) and their labels were approved by the expert committee of FSSAI," according to the statement. "In response to the notice, we have again submitted our detailed response to the authorities regarding statements appearing on the label, which are factual in nature, and supported by scientific literature."